Biosimilars: Eight Is Already More Than Enough For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER's Division of Therapeutic Proteins has received eight pre-IND and IND applications for biosimilar products, and feels a "tremendous strain."